



FOR IMMEDIATE RELEASE

Contact:

Gunilla Traberg

EPAX AS

+47 7013 5960

[gunilla.traberg@epax.com](mailto:gunilla.traberg@epax.com)

## Epax Unveils Latest Study At Issfal 2010

Leading Omega-3 supplier, EPAX AS, will present results from studies related to the treatment and prevention of metabolic syndrome and Type 2 Diabetes at the ISSFAL<sup>1</sup> conference which runs from 29<sup>th</sup> May - 2<sup>nd</sup> June in Maastricht, Netherlands.

Dr Kopecky and collaborators from The Academy of Science of the Czech Republic, who work closely with EPAX AS, will present the data at a presentation from 10.30-12 noon on Monday 31<sup>st</sup> May.

The team will demonstrate that marine Omega-3 fatty acids, in particular DHA (EPAX 1050 TG<sup>2</sup>) can recapture the genetic control of this metabolic disorder caused by being overweight and a sedentary lifestyle. The results show that DHA is effective in restoring efficient fat burning thereby regaining insulin sensitivity which is reduced in this subset of patients.

EPAX is a leading sponsor of the 9<sup>th</sup> ISSFAL conference whose overall theme is “Lipids in Metabolic Health & Disease”. Gunilla Traberg, marketing manager, EPAX AS comments, “We are delighted to be a silver sponsor of this year’s ISSFAL conference. ISSFAL provides us with a great platform to present the findings of this ground breaking study. We are proud that our advanced technological processing systems have enabled us to develop formulas like EPAX 1050 TG which have the potential to improve the health and wellbeing of a great number of people.”

EPAX, who produce the most clinically researched marine Omega-3 ingredients in the world, has placed significant investment in clinical trials for the last thirty years, documenting the efficacy and safety of its Omega-3 concentrates.

Dr Morten Bryhn, MD, Scientific Adviser adds, “The findings of this study show the potential for DHA to have a real impact on the treatment of metabolic syndrome.

---

<sup>1</sup> ISSFAL: International Society of the Studies of Fatty Acids and Lipids

<sup>2</sup> EPAX 1050 TG contains 430mg/g DHA and 60mg/g EPA

“This condition affects a vast number of people and prevalence is increased with age. We are hopeful that the findings will steer a new line of treatment for people suffering or at risk from this potentially serious condition.”

EPAX Omega-3 formulas have been used in more than 100 clinical studies which have been published in peer reviewed scientific journals. EPAX prides itself on its testing and validation processes and places purity, quality and innovation at the heart of all business operations.

- Ends -

#### **Notes to Editors**

For more information on EPAX AS, its products or clinical studies visit [www.epax.com](http://www.epax.com) or contact Gunilla Traberg at [Gunilla.traberg@epax.com](mailto:Gunilla.traberg@epax.com).

For more information on the ISSFAL conference please visit <http://www.unimaas.nl/congresbureau/issfal2010/index.htm>

#### **About EPAX AS:**

EPAX AS offers concentrated marine Omega-3 oils in the business-to-business segment under the brand name EPAX®, available in a wide range of top-quality formulas with different EPA/DHA ratios and concentrations focused on specific health conditions, available in TG and EE versions.

EPAX AS is headquartered in Aalesund with a global sales office in Lysaker/Oslo, Norway. Its production facility in Aalesund is GMP-approved by the Norwegian Medicines Agency for the manufacturing of API products.

The company's operation is certified by Friends of the SEA (FOS) to have a documented sustainable operation - from the fish harvesting in Peru to its finished Omega-3 ingredients in Norway. EPAX is vertically integrated and part of the Austevoll Seafood ASA group - a global pelagic fishery specialist with operations in Chile, Norway and Peru ([www.auss.no](http://www.auss.no)).

All of EPAX's business efforts reflect the company's core commitment: Purity | Quality | Innovation. These values represent EPAX's commitment to offering products that are safe, pure and of consistent quality. EPAX® specifications limits for environmental pollutants and oxidation by-products are well below those set by global authorities' limits. The EPAX formulas are backed by clinical studies.